| chlorthalidone / Generic mfg. |
NCT01033071: Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension. |
|
|
| Completed | 3b | 1071 | US, Canada | Azilsartan medoxomil and chlorthalidone, azilsartan medoxomil plus chlorthalidone, TAK-491CLD, Olmesartan medoxomil and hydrochlorothiazide, Benicar HCT® | Takeda | Essential Hypertension | 10/10 | 11/10 | | |
NCT00591773: Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension |
|
|
| Completed | 3 | 551 | US | Azilsartan medoxomil and chlorthalidone, TAK-491, Edarbi, Chlorthalidone, Thalitone | Takeda | Hypertension | 03/09 | 03/09 | | |
NCT00696384: A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
|
|
| Completed | 3 | 418 | US, RoW | Azilsartan medoxomil, TAK-491, Edarbi, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo | Takeda | Hypertension | 04/09 | 04/09 | | |
NCT00818883: Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension |
|
|
| Completed | 3 | 609 | US, RoW | Azilsartan medoxomil and chlorthalidone, TAK-491, TAK-491CLD, Azilsartan medoxomil and hydrochlorothiazide | Takeda | Essential Hypertension | 11/09 | 11/09 | | |
NCT00695955: One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
|
|
| Completed | 3 | 669 | US, RoW | Azilsartan medoxomil with or without add-on chlorthalidone, TAK-491, Edarbi, Azilsartan medoxomil with or without add-on hydrochlorothiazide | Takeda | Hypertension | 05/10 | 05/10 | | |
NCT00847626 / 2008-004218-28: Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension |
|
|
| Completed | 3 | 1711 | US, RoW | Azilsartan medoxomil and chlorthalidone, TAK-491CLD, Chlorthalidone, Azilsartan medoxomil | Takeda | Hypertension | 05/10 | 07/10 | | |
NCT00846365: Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension |
|
|
| Completed | 3 | 1085 | US, RoW | Azilsartan medoxomil and chlorthalidone, azilsartan medoxomil, chlorthalidone, TAK-491, TAK-491CLD, Olmesartan medoxomil-hydrochlorothiazide, Benicar HCT® | Takeda | Essential Hypertension | 06/10 | 06/10 | | |
NCT00996281 / 2008-008260-28: Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension |
|
|
| Completed | 3 | 837 | Europe | Azilsartan medoxomil and chlorthalidone, TAK-491CLD, Olmesartan medoxomil and hydrochlorothiazide, Benicar HCT®, Olmetec Plus® | Takeda | Essential Hypertension | 11/11 | 11/11 | | |
NCT01309828 / 2010-023098-21: Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease |
|
|
| Completed | 3 | 153 | Europe, RoW | Azilsartan medoxomil and chlorthalidone, TAK-491CLD, Olmesartan medoxomil and hydrochlorothiazide, Olmesartan medoxomil, Hydrochlorothiazide, Benicar hydrochlorothiazide, Olmetec Plus | Takeda | Safety | 10/12 | 10/12 | | |
CARD, NCT01191450: Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension |
|
|
| Unknown status | 3 | 280 | RoW | Chlorthalidone 25 mg + amiloride hydrochloride 5 mg, Diupress® (Eurofarma Laboratórios Ltda.), Higroton® Laboratório Novartis | Eurofarma Laboratorios S.A. | Arterial Hypertension | 11/12 | 11/12 | | |
NCT01456169 / 2011-000220-16: A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone |
|
|
| Completed | 3 | 507 | Europe, RoW | Azilsartan medoxomil/placebo, TAK-491, EDARBI, Azilsartan medoxomil - chlorthalidone, TAK-491CLD, Edarbyclor | Takeda | Essential Hypertension | 12/12 | 01/13 | | |
NCT01850160: Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension |
|
|
| Completed | 3 | 124 | RoW | GROUP A: Valsartan plus Chlorthalidone, Chlorthalidone Drug Combination, Valsartan Drug Combination, Antihypertensive Agents, GROUP B: Valsartan, Angiotensin II Receptor Antagonist, GROUP C: Chlorthalidone, Sodium Chloride Symporter Inhibitors, Diuretics | Farma de Colombia SA | Hypertension | 03/15 | 05/15 | | |
NCT02620163: Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment |
|
|
| Completed | 3 | 381 | RoW | telmisartan/amlodipine 40/5mg, Twynsta 40/5 mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg, telmisartan/amlodipine 80/5mg, Twynsta 80/5 mg, YH22162 80/5/25 mg, telmisartan/amlodipine/chlorthalidone 80/5/25 mg, telmisartan/amlodipine 40/5mg placebo, Twynsta 40/5 mg placebo, YH22162 40/5/12.5 mg placebo, telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg placebo, telmisartan/amlodipine 80/5mg placebo, YH22162 80/5/25 mg placebo, telmisartan/amlodipine/chlorthalidone 80/5/25 mg placebo | Yuhan Corporation | Hypertension | 12/16 | 12/16 | | |
NCT02521233: Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control |
|
|
| Withdrawn | 3 | 0 | NA | Candesartan + Chlorthalidone (8mg+12,5mg), Candesartan + Chlorthalidone, Candesartan + Chlorthalidone (8 mg + 25 mg), losartan+hydrochlorothiazide, Hyzaar ® | EMS | Essential Arterial Hypertension | 05/17 | 08/17 | | |
2016-001809-16: Efficacy and safety of chlorthalidone 25 mg in patients with hypertension. Έλεγχος της αποτελεσματικότητας και ασφάλειας της δόσης 25 mg χλωÏθαλιδόνης σε ασθενείς με Ï…Ï€ÎÏταση. |
|
|
| Completed | 3 | 44 | Europe | Unidone Tablets 25mg/tab, Tablet | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | BP lowering effect of chlorthalidone 25 mg in essential hypertensive patients. ΕπίδÏαση της θεÏαπείας με χλωÏθαλιδόνη στην αÏτηÏιακή πίεση σε ασθενείς με μη θεÏαπευόμενη ή μη ελεγχόμενη ιδιοπαθή Ï…Ï€ÎÏταση., Efficacy and safety of chlorthalidone in patients with hypertension . Αποτελεσματικότητα και ασφάλεια της χλωÏθαλιδόνης σε ασθενείς με Ï…Ï€ÎÏταση., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
NCT02493322: Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control |
|
|
| Not yet recruiting | 3 | 261 | NA | Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg, Olmesartan 20mg + hydrochlorothiazide 12,5mg, Benicar HCT® | EMS | Essential Arterial Hypertension | 06/26 | 11/26 | | |
NCT02483936: Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control |
|
|
| Not yet recruiting | 3 | 348 | NA | Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg, Benicar HCT, Olmesartan 40mg + Hydrochlorothiazide 25mg | EMS | Arterial Hypertension | 06/25 | 09/26 | | |
